Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.
Actavis global R&D president departs to helm Impax Labs
Impax Laboratories ($IPXL) welcomed Frederick Wilkinson, who will lead the company as its president and CEO. Wilkinson comes from Actavis ($ACT), where he served as president of global R&D. He will succeed Larry Hsu, who announced his retirement last year after 18 years and who will remain on the board of directors. Impax release | Actavis release
|
||||||||||||
CRO
> WuXi PharmaTech ($WX) appointed former AstraZeneca ($AZN) executive Steve Yang as executive vice president and chief operating officer. Story
> SynteractHCR has appointed Martine Dehlinger-Kremer as global vice president of medical and regulatory affairs. Release
> Pharmaceutical Product Development (PPD) appointed Bhooshi De Silva as senior vice president of corporate development and strategy. Release
Pharma
> Zoetis ($ZTS) announced today that Glenn David, senior vice president of finance operations, has been named acting chief financial officer. David will succeed executive vice president and chief financial officer Richard Passov, who is leaving the company at the end of April. Release
> Lupin appointed Theresa Stevens as its chief corporate development officer for global operations. Release
> Dr. John Nicholson and James Connolly have resigned from Pivotal Therapeutics' board of directors. Release
Biotech
> Joseph Turgeon moved up at Spectrum Pharmaceuticals ($SPPI) to be the company's president and chief operating officer. Release
> Spark Therapeutics appointed 5 people to support its business, development and research arms: VP of pharmacology and toxicology Linda Couto, VP of financial operations and analysis Linda Hearne, Yi-Lin Emily Liu in clinical operations, Jingmin Zhou in process development and Katie Wachtel in regulatory affairs. Release
> OncoSec Medical brought on Jean Campbell as its executive director of research and development and Dr. Adil Daud as its chief clinical strategist. Release | Release
> Forum Pharmaceuticals has appointed Todd Shegog as senior vice president and chief financial officer. Release
> Orgenesis ($ORGS) appointed Joseph Tenne as its chief financial officer. Release
> Armand Girard joined GlycoMimetics ($GLYC) as the company's vice president of corporate development. Release
> Al Fosmoe has joined Oragenics ($OGEN) as senior vice president of operations and product development. Release
> ContraFect has appointed Julia Gregory as CEO and director. The company also appointed David Low Jr., Michael Otto and Dr. Roger Pomerantz to the board and announced that Sir Richard Sykes has resigned from the board. Release
> India's Biocon has appointed Dr. Arun Chandavarkar as CEO and joint managing director. Release
Biotech IT
> PHT named Andrea Valente its chief operating officer. Release